Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. sophomore Avg
|
New words:
amantadine, BioCryst, cicletanine, consecutive, contingent, cumulative, depleted, embedded, exempt, Feature, iii, inquiry, monotherapy, neuraminidase, peramivir, phantom, predetermined, prove, receipt, reclassification, Relenza, reset, rimantadine, robin, slightly, unsatisfactory, unvested, washington, zanamivir
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.59 Gilead Sciences, Inc. 2004 Equity Incentive Plan
- 10.60 Gilead Sciences, Inc. Severance Plan
- 10.61 Offer Letter Dated April 16, 2008
- 31.1 CEO Certification, As Required by Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 CFO Certification, As Required by Rule 13A-14(A) or Rule 15D-14(A)
- 32 CEO & CFO Certifications, As Required by Rule 13A-14(B) or Rule 15D-14(B)
Related press release
GILD similar filings
Filing view
External links